This compounded formulation of Estriol/Estradiol/Estrone [80%-10%-10%] 0.625-2.5 mg Slow Release Capsules is designed to provide a controlled and prolonged release of hormones, offering sustained therapeutic effects. The formulation is encapsulated in Methocel E4M, a type of controlled-release polymer, which ensures the gradual release of the active ingredients over an extended period of time. This reduces the dosing frequency and improves patient compliance, particularly for those requiring a controlled release profile.

The formulation contains a combination of estriol, estradiol, and estrone in a ratio of 80%-10%-10%. Each of these hormones plays a crucial role in managing various disease states. Estriol, a weaker form of estrogen, helps to mitigate the risk of breast cancer. Estradiol, a stronger form of estrogen, aids in reducing the risk of cardiovascular disease. Estrone, another form of estrogen, helps to lower the risk of endometrial cancer.

The slow release of these hormones ensures a consistent level in the body, reducing the risk of side effects associated with hormone replacement therapy. This formulation is particularly beneficial for patients experiencing menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. It also aids in reducing the risk of postmenopausal osteoporosis and other conditions associated with hormone imbalances.

For healthcare providers, this formulation serves as a valuable tool in the treatment of menopausal symptoms, postmenopausal osteoporosis, and hormone replacement therapy. The combination of estriol, estradiol, and estrone in this formulation, along with the slow release capsule, ensures a more consistent level of hormones in the body, thereby reducing the risk of side effects associated with hormone replacement therapy.

If you have any questions about this formulation, please do not hesitate to contact us at Bayview Pharmacy. Our team of compounding pharmacists is here to assist you with any queries you may have.

This compounded formulation of Estriol/Estradiol/Estrone [80%-10%-10%] 0.625-2.5 mg Slow Release Capsules is designed to provide a controlled and prolonged release of the active ingredients. The formulation is encapsulated with Methocel E4M, a controlled-release polymer, which allows for a gradual release of the medication over an extended period of time. This slow release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance.

The formulation is primarily used for the treatment of menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. It may also be prescribed for the treatment of osteoporosis and to reduce the risk of developing endometrial hyperplasia in postmenopausal women. Additionally, it can be used to treat hypoestrogenism, a condition characterized by insufficient estrogen production in the body.

However, this formulation is not recommended for use in pregnant or breastfeeding women due to potential harm to the fetus or infant. It is also contraindicated in women with a history of breast cancer, endometrial cancer, or other estrogen-dependent cancers, as well as in women with a history of stroke, blood clots, or liver disease.

Patients should be aware of potential side effects, which may include nausea, headache, breast tenderness, and fluid retention. There is also an increased risk of developing endometrial hyperplasia, breast cancer, and other estrogen-dependent cancers. Furthermore, this formulation may interact with other medications, such as anticoagulants, insulin, and certain antibiotics.

Prescribers should exercise caution when prescribing this formulation to patients with a history of stroke, blood clots, or liver disease, as well as to those with a history of breast cancer, endometrial cancer, or other estrogen-dependent cancers. It is also important to consider potential interactions with other medications, such as anticoagulants, insulin, and certain antibiotics.

If you have any questions about this formulation or its potential interactions, please do not hesitate to reach out for further information.

This compounded formulation combines estriol, estradiol, and estrone in a ratio of 80%-10%-10%, encapsulated in slow release capsules containing 0.625-2.5 mg of each hormone. It is designed to treat a variety of conditions, including menopausal symptoms, osteoporosis, and as part of hormone replacement therapy.

The estriol component is primarily used to alleviate menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. It also plays a role in reducing the risk of osteoporosis and in maintaining bone density. Estradiol, like estriol, is used to treat menopausal symptoms and to help maintain bone density, thereby reducing the risk of osteoporosis. Estrone, on the other hand, is used not only to treat menopausal symptoms and maintain bone density but also to reduce the risk of breast cancer.

The unique feature of this formulation is the slow release capsules. These capsules are formulated with Methocel E4M, a type of controlled-release polymer. This design allows for a gradual and sustained release of the hormones into the body, providing a more consistent level of hormones over time. This controlled release helps to mitigate the risk of side effects associated with sudden changes in hormone levels.

While this formulation is generally well tolerated, potential side effects may occur. These can include nausea, headache, breast tenderness, and weight gain. It is crucial to discuss any potential side effects with your healthcare provider before starting this medication.

If you have any questions about this formulation or its mechanism of action, please do not hesitate to reach out. We are here to provide the necessary information and support.

This Estriol/Estradiol/Estrone [80%-10%-10%] 0.625-2.5 mg Slow Release Capsule formulation is designed to provide a controlled and prolonged release of the active ingredients. The formulation is encapsulated with Methocel E4M, a controlled-release polymer, which allows for the gradual release of the medication over an extended period. This slow release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications requiring a controlled release profile.

The formulation is used to treat a variety of conditions, including endometriosis, premenstrual syndrome, polycystic ovarian syndrome, and postmenopausal bleeding. It may also be used to reduce the risk of developing certain types of cancer, such as breast and ovarian cancer. Additionally, this formulation may be used to reduce the risk of developing cardiovascular disease, improve bone density, reduce the risk of fractures, and potentially reduce the risk of developing dementia and Alzheimer's disease. It may also be used to reduce the risk of developing depression and anxiety.

It is crucial to understand that this formulation should only be used under the supervision of a healthcare provider. The dosage and duration of treatment should be tailored to the individual patient's needs and should be based on the patient's medical history, current symptoms, and other factors. Patients should be monitored closely for any adverse effects, and the dosage should be adjusted accordingly.

If you have any questions about the use of this formulation, please do not hesitate to reach out. It is our goal to provide you with the most comprehensive and accurate information to ensure your health and well-being.